Approved: A New Rx for Liposarcoma
This week, the US Food and Drug Administration (FDA) approved Eisai Inc.'s drug derived from sea sponge for a rare type of soft tissue cancer.
FDA Approves New Liposarcoma Rx
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.
Ultra-convenient, Ultra-safe, Ultra-effective
Ultrasound fusion imaging (UFI) biopsies are as safe and effective as other methods of detecting bone and soft-tissue cancers, according to a new study from Henry Ford Hospital.
Researchers at Oregon Health & Science University Doernbecher Children's Hospital have identified the cell of origin for muscle cancer known as sarcoma.